BR112016006813A2 - Composição imunoterapêutica nova e seus usos - Google Patents
Composição imunoterapêutica nova e seus usosInfo
- Publication number
- BR112016006813A2 BR112016006813A2 BR112016006813A BR112016006813A BR112016006813A2 BR 112016006813 A2 BR112016006813 A2 BR 112016006813A2 BR 112016006813 A BR112016006813 A BR 112016006813A BR 112016006813 A BR112016006813 A BR 112016006813A BR 112016006813 A2 BR112016006813 A2 BR 112016006813A2
- Authority
- BR
- Brazil
- Prior art keywords
- ara
- immunotherapeutic composition
- composition
- allergy
- present
- Prior art date
Links
- 230000001024 immunotherapeutic effect Effects 0.000 title abstract 4
- 206010020751 Hypersensitivity Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 2
- 230000007815 allergy Effects 0.000 abstract 2
- 235000017060 Arachis glabrata Nutrition 0.000 abstract 1
- 241001553178 Arachis glabrata Species 0.000 abstract 1
- 235000010777 Arachis hypogaea Nutrition 0.000 abstract 1
- 235000018262 Arachis monticola Nutrition 0.000 abstract 1
- 206010016946 Food allergy Diseases 0.000 abstract 1
- 208000008267 Peanut Hypersensitivity Diseases 0.000 abstract 1
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 239000013566 allergen Substances 0.000 abstract 1
- 235000014571 nuts Nutrition 0.000 abstract 1
- 235000020232 peanut Nutrition 0.000 abstract 1
- 201000010853 peanut allergy Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013903686A AU2013903686A0 (en) | 2013-09-25 | Novel immunotherapeutic composition and uses thereof | |
| PCT/AU2014/050249 WO2015042664A1 (en) | 2013-09-25 | 2014-09-25 | Novel immunotherapeutic composition and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016006813A2 true BR112016006813A2 (pt) | 2017-09-19 |
Family
ID=52741648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016006813A BR112016006813A2 (pt) | 2013-09-25 | 2014-09-25 | Composição imunoterapêutica nova e seus usos |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11266737B2 (https=) |
| EP (2) | EP3049098A4 (https=) |
| JP (1) | JP7007534B2 (https=) |
| KR (1) | KR20160075532A (https=) |
| CN (2) | CN105992589A (https=) |
| AU (2) | AU2014328483B2 (https=) |
| BR (1) | BR112016006813A2 (https=) |
| MX (1) | MX376449B (https=) |
| RU (1) | RU2689552C2 (https=) |
| WO (1) | WO2015042664A1 (https=) |
| ZA (1) | ZA201602043B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2914286T3 (pl) | 2012-10-30 | 2022-01-31 | Aravax Pty Ltd | Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania |
| WO2015042664A1 (en) | 2013-09-25 | 2015-04-02 | Monash University | Novel immunotherapeutic composition and uses thereof |
| EP3938053A4 (en) * | 2019-03-13 | 2023-03-22 | Psomagen, Inc. | EPITOP-BASED APPROACH TO ALLERGY TREATMENTS AND INHIBITORS FOR CROHN'S DISEASE |
| US20240042016A1 (en) * | 2020-12-30 | 2024-02-08 | The Regents Of The University Of Michigan | Nanoemulsion vaccine compositions and methods for suppressing reactivity to multiple food allergens |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5558869A (en) | 1992-12-30 | 1996-09-24 | University Of Arkansas | Major peanut allergen ara h II |
| EP0873135B1 (en) | 1995-12-29 | 2009-07-22 | The University of Arkansas | Peanut allergens and methods |
| US6835824B1 (en) * | 1995-12-29 | 2004-12-28 | University Of Arkansas | Peanut allergens and methods |
| US20030202980A1 (en) | 1995-12-29 | 2003-10-30 | Caplan Michael J. | Methods and reagents for decreasing clinical reaction to allergy |
| GB2348808B (en) | 1998-01-09 | 2003-03-19 | Circassia Ltd | Methods and compositions for desensitisation |
| DE69921773D1 (de) | 1998-01-16 | 2004-12-16 | Univ Johns Hopkins | Orale verabreichung von nukleinsäure-impstoffen durch partikelkomplexe |
| AU743647B2 (en) | 1998-01-31 | 2002-01-31 | Mt. Sinai School Of Medicine Of New York University | Methods and reagents for decreasing allergic reactions |
| AU3085299A (en) | 1998-03-12 | 1999-09-27 | Board Of Trustees Of The University Of Arkansas, The | Tertiary structure of peanut allergen ara h 1 |
| AU3717600A (en) | 1999-03-02 | 2000-09-21 | Board Of Trustees Of The University Of Arkansas, The | Methods and reagents for decreasing clinical reaction to allergy |
| WO2000051647A2 (en) | 1999-03-03 | 2000-09-08 | Mount Sinai School Of Medicine Of New York University | Animal model of allergies |
| WO2000054803A2 (en) | 1999-03-16 | 2000-09-21 | Panacea Pharmaceuticals, Llc | Immunostimulatory nucleic acids and antigens |
| US9289487B2 (en) * | 1999-09-14 | 2016-03-22 | Antigen Express, Inc. | II-key/antigenic epitope hybrid peptide vaccines |
| US20030235594A1 (en) | 1999-09-14 | 2003-12-25 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| AU2065801A (en) | 1999-12-06 | 2001-06-12 | Panacea Pharmaceuticals, Llc | Passive desensitization |
| US20020147140A1 (en) | 2000-01-31 | 2002-10-10 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| RU2285042C2 (ru) | 2000-11-16 | 2006-10-10 | Альк-Абелло А/С | Новые мутантные аллергены |
| ATE414773T1 (de) | 2000-11-16 | 2008-12-15 | Alk Abello As | Mutante allergene |
| AU2002306850A1 (en) | 2001-03-16 | 2002-10-03 | Panacea Pharmaceuticals | Methods and reagents for decreasing clinical reaction to allergy |
| GB0110432D0 (en) | 2001-04-27 | 2001-06-20 | Plant Bioscience Ltd | Lantibiotic production |
| MXPA03010037A (es) | 2001-05-01 | 2004-06-30 | Univ California | Moleculas de fusion y metodos para tratamiento de enfermedades inmunes. |
| EP1453539B1 (en) | 2001-12-05 | 2008-11-19 | Circassia Limited | Immunotherapeutic methods and systems |
| US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
| CA2499123A1 (en) * | 2002-09-17 | 2004-04-15 | Antigen Express, Inc. | Ii-key/antigenic epitope hybrid peptide vaccines |
| US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
| US8057800B2 (en) * | 2004-06-10 | 2011-11-15 | Circassia Limited | Immunointeractive molecules and uses thereof |
| US7566456B2 (en) | 2005-06-23 | 2009-07-28 | Haiming Chen | Allergen vaccine proteins for the treatment and prevention of allergic diseases |
| FI20075063A0 (fi) * | 2007-02-01 | 2007-02-01 | Vactech Oy | Allergisen herkistymisen estäminen |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| NZ583362A (en) | 2007-08-15 | 2012-06-29 | Circassia Ltd | Peptide with reduced dimer formation |
| GB2455108A (en) | 2007-11-28 | 2009-06-03 | Circassia Ltd | T-Cell dependent method for detecting non-allergic or intrinsic disorders |
| EP2140880B1 (en) | 2008-07-04 | 2012-11-14 | HAL Allergy Holding B.V. | Modification of allergens |
| EP2331124A1 (en) | 2008-08-15 | 2011-06-15 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of il-10 production |
| ES2378870T5 (es) | 2008-08-15 | 2016-02-03 | Circassia Limited | Vacuna que comprende péptidos Amb a 1 para uso en el tratamiento de alergia a ambrosía |
| GB0821806D0 (en) | 2008-11-28 | 2009-01-07 | Circassia Ltd | Compositions with reduced dimer formation |
| EP2233502A1 (en) | 2009-03-27 | 2010-09-29 | Deutsches Rheuma-Forschungszentrum Berlin | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them |
| EP2478373B1 (en) | 2009-09-14 | 2019-01-09 | Icahn School of Medicine at Mount Sinai | Methods for characterizing antibody binding affinity and epitope diversity in food allergy |
| WO2011106645A1 (en) | 2010-02-26 | 2011-09-01 | Benaroya Research Institute | Direct analysis of antigen-specific immune response |
| US8835361B2 (en) | 2010-06-01 | 2014-09-16 | The Curators Of The University Of Missouri | High-throughput quantitation of crop seed proteins |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US20140080730A1 (en) | 2011-03-20 | 2014-03-20 | The Regents Of The University Of Colorado, A Body Corporate | Method for predicting severity of allergic reaction |
| MX374963B (es) | 2011-04-29 | 2025-03-06 | Selecta Biosciences Inc | Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos. |
| JP2013040138A (ja) | 2011-08-17 | 2013-02-28 | Univ Of Tsukuba | 活性化型リコンビナント花粉アレルゲンの作製方法 |
| WO2013036301A1 (en) | 2011-09-06 | 2013-03-14 | Selecta Biosciences, Inc. | Induced tolerogenic dendritic cells for inducing regulatory b cells |
| CN102533781B (zh) | 2011-12-30 | 2013-09-11 | 华南师范大学 | 花生2s-4b蛋白在诱导细胞凋亡中的应用 |
| CN102816232B (zh) | 2011-12-30 | 2014-07-16 | 华南师范大学 | 花生2s-4b蛋白及其生产方法 |
| CA2861003C (en) | 2012-01-13 | 2023-03-28 | Julius-Maximilians-Universitat Wurzburg | Dual antigen-induced bipartite functional complementation |
| AU2012382406B2 (en) | 2012-06-15 | 2017-12-07 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of allergies |
| PL2914286T3 (pl) | 2012-10-30 | 2022-01-31 | Aravax Pty Ltd | Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania |
| DK2914285T3 (en) | 2012-11-01 | 2017-02-27 | Veterinærinstituttet | New fusion proteins for the treatment of allergic diseases |
| MY193724A (en) | 2013-03-15 | 2022-10-27 | Sementis Ltd | Immune modulation |
| WO2015042664A1 (en) | 2013-09-25 | 2015-04-02 | Monash University | Novel immunotherapeutic composition and uses thereof |
-
2014
- 2014-09-25 WO PCT/AU2014/050249 patent/WO2015042664A1/en not_active Ceased
- 2014-09-25 JP JP2016517506A patent/JP7007534B2/ja active Active
- 2014-09-25 KR KR1020167010829A patent/KR20160075532A/ko not_active Ceased
- 2014-09-25 EP EP14848639.2A patent/EP3049098A4/en not_active Withdrawn
- 2014-09-25 EP EP25193759.5A patent/EP4710935A3/en active Pending
- 2014-09-25 CN CN201480052398.1A patent/CN105992589A/zh not_active Withdrawn
- 2014-09-25 AU AU2014328483A patent/AU2014328483B2/en active Active
- 2014-09-25 CN CN202511626174.3A patent/CN121714673A/zh active Pending
- 2014-09-25 BR BR112016006813A patent/BR112016006813A2/pt not_active Application Discontinuation
- 2014-09-25 RU RU2016115732A patent/RU2689552C2/ru active
- 2014-09-25 MX MX2016003363A patent/MX376449B/es active IP Right Grant
- 2014-09-25 US US15/024,666 patent/US11266737B2/en active Active
-
2016
- 2016-03-29 ZA ZA2016/02043A patent/ZA201602043B/en unknown
-
2020
- 2020-02-07 AU AU2020200883A patent/AU2020200883B2/en active Active
-
2022
- 2022-02-15 US US17/672,571 patent/US11986522B2/en active Active
-
2024
- 2024-04-22 US US18/642,536 patent/US20240415955A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11266737B2 (en) | 2022-03-08 |
| AU2020200883B2 (en) | 2022-05-12 |
| AU2020200883A1 (en) | 2020-02-27 |
| RU2016115732A (ru) | 2017-10-30 |
| US20220280637A1 (en) | 2022-09-08 |
| ZA201602043B (en) | 2022-08-31 |
| JP7007534B2 (ja) | 2022-01-24 |
| WO2015042664A1 (en) | 2015-04-02 |
| RU2016115732A3 (https=) | 2018-06-19 |
| EP4710935A3 (en) | 2026-05-06 |
| US20160375130A1 (en) | 2016-12-29 |
| CN105992589A (zh) | 2016-10-05 |
| EP3049098A1 (en) | 2016-08-03 |
| US11986522B2 (en) | 2024-05-21 |
| CN121714673A (zh) | 2026-03-24 |
| AU2014328483A1 (en) | 2016-04-21 |
| AU2014328483B2 (en) | 2019-11-14 |
| CA2925480A1 (en) | 2015-04-02 |
| RU2689552C2 (ru) | 2019-05-28 |
| EP4710935A2 (en) | 2026-03-18 |
| JP2016533341A (ja) | 2016-10-27 |
| US20240415955A1 (en) | 2024-12-19 |
| EP3049098A4 (en) | 2017-08-16 |
| MX376449B (es) | 2025-03-07 |
| MX2016003363A (es) | 2016-09-23 |
| KR20160075532A (ko) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201600002A (es) | Bencil-1h-pirazolo[3,4-b]piridinas y su uso | |
| CR20140327A (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
| CR20150476A (es) | Oxopyridine derivados sustituidos y su uso en el tratamiento de trastornos cardiovasculares | |
| BR112015027281A8 (pt) | usos de uma população de nanocarreadores sintéticos que são fixados a imunossupressores e composição compreendendo a referida população de nanocarreadores | |
| DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
| MX389847B (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
| BR112012022755A2 (pt) | composição com bactérias probióticas para uso no tratamento de distúrbios imunológicos | |
| BR112016010422A8 (pt) | suplemento dietético, e uso de uma composição | |
| BR112017007543A2 (pt) | peptídeos com propriedades anti-inflamatórias | |
| BR112017008284A8 (pt) | Bifidobactérias ativadas e métodos para uso das mesmas | |
| UY35693A (es) | Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso | |
| BR112015022472A2 (pt) | método e sistema para prever a resposta a tratamentos para transtornos mentais | |
| MX2016004340A (es) | Compuestos heterociclicos y usos de los mismos. | |
| BR112016011792A2 (pt) | Derivados de imidazopiridina como moduladores de atividade de tnf | |
| EP2968404A4 (en) | Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction | |
| CL2016000392A1 (es) | Análogos de cortistatina para el tratamiento de enfermedades con componente inflamatorio y/o inmune | |
| UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
| BR112015015864A8 (pt) | composição farmacêutica, e, uso de uma composição farmacêutica | |
| BR112018003780A2 (pt) | composições que compreendem um composto de urolitina | |
| BR102015012091A8 (pt) | método para a preparação de uma solução de albumina humana, e, composição | |
| BR112015018335A2 (pt) | Composições nutritivas contendo um componente peptídico com propriedades anti-inflamatórias e usos das mesmas | |
| MX388428B (es) | Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de animo | |
| BR112016006813A2 (pt) | Composição imunoterapêutica nova e seus usos | |
| DOP2016000076A (es) | Tienouracilcarboxamidas cíclicas y usos de las mismas | |
| BR112017007813A2 (pt) | composições oftalmológicas, método de prevenção, redução ou tratamento de transtornos causados por olhos secos e uso de ciclosporina e trealose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |